You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Real-World Experience

Positive Perspectives: Understanding the Unmet Need of PLHIV

Positive Perspectives Study, Wave 2 (Positive Perspectives 2) is one of the largest, global, HIV patient-reported outcomes studies to date, involving 2,389 people living with HIV (PLHIV) across 25 countries globally, including Ireland (n=50).1,2,3* The research explores the aspirations and attitudes of a diverse range of PLHIV, revealing how they feel about their HIV care and relationships with their health care providers (HCPs).

Results from Positive Perspectives 2 reveal the experiences of PLHIV, reflecting changes in HIV care and providing insights into aspects of quality of life that need to be addressed across several key areas including:

asset3
 Impact of polypharmacy
asset-28
PLHIV-HCP Engagement
asset2
 Undetectable = Untransmittable (U=U)
asset5
HIV and Women
asset1
Ageing well with HIV

Further information in relation to this study can be found on our Positive Perspectives 2 Webpage: https://livlife.com/en-ie/positive-perspectives/

Positive Perspectives 2 Highlights

Is Polypharmacy linked to poorer Health Outcomes?

People with polypharmacy reported significantly poorer health outcomes compared with those without polypharmacy, independent of existing comorbidities (n=50)2

polypharmacy-graph

  Polypharmacy was defined as taking 5 or more pills per day for HIV or non-HIV conditions, or taking medicines currently for 5 or more conditions, including HIV. All differences between people with a report of polypharmacy compared with those not reporting polypharmacy were significant at p<0.05.1

Base: All respondents in Ireland, n=50

How many PLHIV reported side effects, DDIs and concerns around the long-term effects of ART?

Among the total number of participants in Ireland (n=50)3

Concerns around the Long-Term Effects of ART Concerns around the Long-Term Effects of ART
NA NA

Positive Perspectives 2 Highlights

Is Polypharmacy linked to poorer Health Outcomes?

People with polypharmacy reported significantly poorer health outcomes compared with those without polypharmacy, independent of existing comorbidities (n=2,112)¹

  Polypharmacy was defined as taking 5 or more pills per day for HIV or non-HIV conditions, or taking medicines currently for 5 or more conditions, including HIV. All differences between people with a report of polypharmacy compared with those not reporting polypharmacy were significant at p<0.05.¹

How many PLHIV reported side effects, DDIs and concerns around the long-term effects of ART?

Among the total number of participants (n=2,112)¹:

Positive Perspectives 2 – take a closer look 

Explore a visual summary of the key results from the study in the Ireland sample

The Positive Perspective Infographic

Explore the results in full

The Positive Perspective Results Report

* The Positive Perspectives study expanded from 2,112 participants in 24 countries to 2,389 participants in 25 countries following the publication of the first sub-study.

References:

  1. Okoli C, des los Rios P, Eremin A, Brough G, Young B, Short D. Relationship between polypharmacy and quality of life among people in 24 countries living with HIV. Prev Chronic Dis. 2020;17:E22.doi:10.5888/pcd17.190359.
  2. GSK/ViiV 2020. Data on File. NP-IE-HVX-BRFS-200002. Market Research PP2 Ireland - Sub Analysis
  3. GSK/ViiV 2020. Data on File. NP-IE-HVX-BRFS-200001. Market Research PP2 Ireland Country Report.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.

Date of preparation: March 2021 PM-IE-DLL-WCNT-200023